IP Library Granted Patent US 9,556,226
Granted Patent B2
US 9,556,226 · App. 14/777,321 · Granted Jan 31, 2017

Peptides with antifungal activity and methods of using the peptides

Inventors: Suresh Kumar Thallapuranam (Fayetteville, AR); David S. McNabb (Fayetteville, AR); Yazan Hussien Akkam (Fayetteville, AR); Duy Tu Nguyen (Fayetteville, AR)
Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
C07K7/06A01N37/18A01N37/46A01N47/44A61K38/04A61K38/08A61K38/12C07K7/08C07K14/4723
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,556,226
App. No.
14/777,321
Granted
Jan 31, 2017
Kind
B2
Abstract

Compositions with antifungal activity and methods of using such compositions are provided herein. In particular the compositions are peptides of SEQ ID NO: 1 and variations thereof. The peptides may contain L or D amino acids and may be circularized, dimerized or otherwise modified to make the compositions resistant to proteolysis. The compositions may be used to inhibit microbial growth and in particular fungal growth.

Claims (15)

1. An antifungal composition comprising a peptide of SEQ ID NO: 3 (Y-K-R-K-F-F-K-R-K-Y) or SEQ ID NO:4 (Y-K-R-K-F-K-R-K-Y).

2. The composition of claim 1 , wherein the amino acids are D amino acids.

3. The composition of claim 1 , further comprising a cysteine in the peptide, wherein the cysteine is positioned at the N-terminus, the C-terminus or in both of these positions.

4. The composition of claim 1 , wherein the peptide is circularized.

5. The composition of claim 1 , wherein the peptide is no more than 12 amino acids long.

6. The composition of claim 1 , wherein the peptide is not circularized or is N-terminally modified.

7. A pharmaceutical composition comprising the composition of claim 1 .

8. A method of treating a microbial infection in a subject, comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

9. The method of claim 8 , wherein the microbial infection is a fungal infection.

10. The method of claim 9 , wherein the fungal infection is a Candida, Aspergillus, Histoplasma , or Cryptococcus infection.

11. The method of claim 8 , wherein the subject is human or a non-human mammal.

12. The method of claim 8 , wherein the composition is administered via a route selected from oral, topical, intranasal, intraperitoneal, parenteral, intravenous, intramuscular, subcutaneous, intrathecal, transcutaneous, nasopharyngeal, or via transmucosal absorption.

13. A method of inhibiting microbial growth, comprising applying the composition of claim 1 to an object to inhibit microbial growth, wherein the object is selected from the group consisting of a food, a surface or a liquid.

14. The method of claim 13 , wherein the microbial growth is growth of a fungus selected from the group consisting of a Candida, Aspergillus, Histoplasma , and Cryptococcus fungus.

15. A method of inhibiting microbial growth in, on or with a cell, comprising contacting a cell with the composition of claim 1 , wherein microbial growth in, on or with the cell is inhibited.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2016
From: THALLAPURANAM, SURESH KUMAR; MCNABB, DAVID S.; AKKAM, YAZAN HUSSIEN; NGUYEN, DUY TU
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 039909/0060 →
CONFIRMATORY LICENSE Recorded May 22, 2016
From: UNIVERSITY OF ARKANSAS AT FAYETTEVILLE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038772/0389 →
Continuity (2)
Provisional Application 61789307 · Mar 15, 2013
Related Publication 20160039873A1 · Feb 11, 2016